Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000949 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
A Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 15
- Study locations
NCT00000949 is a Phase 3 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 460 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 15 study locations across 13 states.
The verdict
NCT00000949, a Phase 3 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug therapy. The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. There is strong evidence that rIL-2 increases CD4 cell counts (cells of the immune system that fight infection). This study examines the effect of 2 different amounts of rIL-2 on CD4 cell count and the amount of HIV in the blood (viral burden).
Conditions Studied
Interventions
- DRUG Aldesleukin
Study Locations (15)
Michigan
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
- Henry Ford Hosp - Detroit
New Jersey
- Southern New Jersey AIDS Clinical Trials - Camden
- North Jersey Community Research Initiative - Newark
California
- Community Consortium / UCSF - San Francisco
Colorado
- Denver CPCRA / Denver Public Hlth - Denver
District of Columbia
- Washington Reg AIDS Prog / Dept of Infect Dis - Washington D.C.
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Illinois
- AIDS Research Alliance - Chicago - Chicago
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Est. Completion | 2000-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000949
The ClinicalTrials.gov registry entry for NCT00000949 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Aldesleukin is the first listed.
NCT00000949 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Michigan, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT00000949 about?
NCT00000949 is a clinical study titled "A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3". The purpose of this study is to examine how rIL-2 affects HIV-positive patients with CD4 counts over 300 cells/mm3 who are on anti-HIV drug therapy. The drug rIL-2 has been shown to increase CD4 cell counts, which help the body fight off HIV. There is strong evidence that rIL-2 increases CD4 cell c...
What is the current status of trial NCT00000949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. Estimated completion is 2000-07.
What conditions does trial NCT00000949 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000949?
The interventions under investigation include: Aldesleukin (DRUG).
Who is sponsoring clinical trial NCT00000949?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000949 being conducted?
This trial has 15 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.